Pathologists Tend to Reclassify Prior Nonmalignant Diagnoses

This article originally appeared here.
Share this content:
Pathologists Tend to Reclassify Prior Nonmalignant Diagnoses
Pathologists Tend to Reclassify Prior Nonmalignant Diagnoses

(HealthDay News) – For dermatopathologists, there is a trend toward reclassification of prior nonmalignant diagnoses of severely atypical dysplastic nevi as malignant, according to a study published in the September issue of the Journal of the American Academy of Dermatology.

Jason E. Frangos, MD, from Harvard Medical School in Boston, and colleagues had a group of 9 dermatopathologists review retrieved pathology files and reevaluate 29 cases of dysplastic nevi with severe atypia and 11 cases of thin radial growth-phase melanoma, originally diagnosed in 1988 through 1990.

The researchers found the mean number of melanoma diagnoses in the revaluation to be 18, an increase from the 11 original diagnoses of melanoma. In all 11 cases, a majority agreed with the original melanoma diagnosis. In 4 of the 29 cases originally reported as dysplastic nevus with severe atypia, a majority of current raters diagnosed melanoma. Interrater agreement over time was excellent for cases originally diagnosed as melanoma (kappa, 0.88), and fair for cases originally diagnosed as severely atypical dysplastic nevus (kappa, 0.47).

"The results of this study provide support for the hypothesis that dermatopathologists are more likely to diagnose thin superficial spreading melanoma in biopsy specimens that were reported as dysplastic nevi with severe atypia in the past, e.g., some 20 years ago," the authors write.

Full Text (subscription or payment may be required)

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs